as was the case for the antibody specific for very late antigen 4 (also known as α4 integrin), natalizumab (Tysabri; Biogen Idec/Elan) 22. In conclusion, we propose that PIDs may provide useful ...

natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and transendothelial migration via the α4β1 integrin pathway. Natalizumab demonstrated twice the efficacy of injectable ...